Novavax (NASDAQ:NVAX – Get Rating) had its target price decreased by Cowen from $150.00 to $110.00 in a research report released on Tuesday, Stock Target Advisor reports.
据Stock Target Advisor报道，在周二发布的一份研究报告中，考恩将诺华公司(纳斯达克代码：NVAX-GET评级)的目标价从150.00美元下调至110.00美元。
A number of other equities research analysts have also recently weighed in on NVAX. Cowen dropped their price target on shares of Novavax from $150.00 to $110.00 and set an outperform rating for the company in a research report on Tuesday. Cantor Fitzgerald raised their price objective on shares of Novavax from $146.00 to $168.00 in a research note on Wednesday, June 8th. Bank of America started coverage on shares of Novavax in a research note on Friday, May 20th. They issued an underperform rating and a $35.00 price objective for the company. Finally, B. Riley lowered their price objective on shares of Novavax from $181.00 to $171.00 in a research note on Friday, July 22nd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company. According to MarketBeat, Novavax currently has an average rating of Hold and a consensus target price of $151.00.
Novavax Price Performance
Shares of NVAX opened at $40.28 on Tuesday. Novavax has a 1-year low of $34.88 and a 1-year high of $277.80. The stock has a market cap of $3.15 billion, a PE ratio of -2.28, a P/E/G ratio of 0.06 and a beta of 1.52. The firm has a 50-day simple moving average of $53.49 and a two-hundred day simple moving average of $63.48.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. Qube Research & Technologies Ltd purchased a new position in Novavax in the first quarter worth approximately $9,839,000. IFM Investors Pty Ltd lifted its stake in Novavax by 19.6% in the first quarter. IFM Investors Pty Ltd now owns 11,096 shares of the biopharmaceutical company's stock worth $817,000 after acquiring an additional 1,819 shares during the last quarter. Nomura Asset Management Co. Ltd. lifted its stake in Novavax by 8.5% in the fourth quarter. Nomura Asset Management Co. Ltd. now owns 13,990 shares of the biopharmaceutical company's stock worth $2,002,000 after acquiring an additional 1,100 shares during the last quarter. Banque Cantonale Vaudoise lifted its stake in Novavax by 3,018.2% in the first quarter. Banque Cantonale Vaudoise now owns 11,631 shares of the biopharmaceutical company's stock worth $857,000 after acquiring an additional 11,258 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its stake in Novavax by 2.2% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 178,351 shares of the biopharmaceutical company's stock worth $13,136,000 after acquiring an additional 3,814 shares during the last quarter. Hedge funds and other institutional investors own 43.91% of the company's stock.
机构投资者最近增持或减持了该公司的股份。Qube Research&Technologies Ltd在第一季度购买了Novavax的一个新头寸，价值约983.9万美元。IFM Investors Pty Ltd在第一季度增持了19.6%的Novavax股份。IFM Investors Pty Ltd在上个季度增持了1,819股后，现在拥有这家生物制药公司11,096股股票，价值817,000美元。野村资产管理有限公司(Nomura Asset Management Co.Ltd.)第四季度增持Novavax股份8.5%。野村资产管理有限公司(Nomura Asset Management Co.Ltd.)在上个季度增持了1,100股野村资产管理公司(Nomura Asset Management Co.)股票后，目前持有这家生物制药公司13,990股股票，价值2,002,000美元。第一季度，Canonale Vaudoise银行增持了Novavax 3018.2%的股份。Canonale Vaudoise银行现在拥有这家生物制药公司11631股票，价值85.7万美元，在上个季度额外购买了11258股。最后，三井住友信托控股有限公司(Sumitomo Mitsui Trust Holdings Inc.)在第一季度增持了Novavax 2.2%的股份。三井住友信托控股有限公司(Sumitomo Mitsui Trust Holdings Inc.)目前持有这家生物制药公司178,351股股票，价值13,136,000美元，该公司在上个季度增持了3,814股股票。对冲基金和其他机构投资者持有该公司43.91%的股份。
Novavax, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.
- Get a free copy of the StockNews.com research report on Novavax (NVAX)
- Are 3M, Honeywell, GE Buys After Quarterly Reports?
- This Defense Stock Has Bullish Fundamentals AND Technicals
- CVS and Walgreens Show Why Investment Objectives Matter
- Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
- Are Medtronic And Intuitive Surgical Poised For Big Growth?
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.